Skip to main content
Full access
Letter to the Editor
Published Online: 1 September 2001

Antidepressant Effects of Hydrocortisone

To the Editor: We read with great interest the report by Charles DeBattista, D.M.H., M.D., and co-authors (1) of their double-blind, placebo-controlled trial with depressed patients in which the patients who received 15 mg of intravenous hydrocortisone demonstrated a significantly greater reduction in Hamilton Depression Rating Scale scores over a 24-hour period than those who received placebo or ovine corticotropin-releasing hormone. This mood-elevating effect of hydrocortisone has previously been noted by Goodwin et al. (2). The authors considered a number of explanations for the finding of the antidepressant-like effects of hydrocortisone injections. They hypothesized that the hydrocortisone may have enhanced negative feedback and thereby reduced hypothalamic-pituitary-adrenal axis activity overall, enhanced dopamine activity, corrected a state of hypocortisolemia, or increased β endorphin levels. We suggest an alternative explanation—namely, that the antidepressant effect of hydrocortisone may have been mediated by means of the serotonin (5-HT) system.
The antidepressant effects of tricyclic antidepressants, serotonin-specific reuptake inhibitors, lithium, and ECT are possibly mediated by an attenuation of inhibitory somatodendritic 5-HT1A receptor function, with a subsequent facilitation of 5-HT transmission (3). Elevated plasma cortisol levels, induced by acute stress or administration of hydrocortisone, attenuate somatodendritic 5-HT1A receptor function in both mice and humans, thereby facilitating 5-HT1A neurotransmission in an antidepressant-like manner (46). This is in marked contrast to the effects of long-term elevation of corticosteroids, which reduce postsynaptic 5-HT1A receptor numbers, an effect that may promote depression (7). We propose that this attenuation of somatodendritic 5-HT1A receptor function is the basis of the mood-elevating effects produced by hydrocortisone in the study by Dr. DeBattista et al. and illustrates a potential neurobiological basis of resilience in the face of psychosocial stress. Failure of this response, due, for example, to deficient glucocorticoid receptor function, may be central to the development of depressive illness (8).

References

1.
DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF: Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry 2000; 157:1334-1337
2.
Goodwin G, Muir W, Seckl J, Bennie J, Carroll S, Dick H, Fink G: The effects of cortisol infusion upon hormone secretion from the anterior pituitary and subjective mood in depressive illness and in controls. J Affect Disord 1992; 26:73-83
3.
Goodwin G: The effects of antidepressant treatments and lithium upon 5-HT1A receptor function. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13:445-451
4.
Young AH, Sharpley AL, Campling GM, Hockney RA, Cowen PJ: Effects of hydrocortisone on brain 5-HT function and sleep. J Affect Disord 1994; 32:139-146
5.
Young AH, Goodwin GM, Dick H, Fink G: Effects of glucocorticoids on 5-HT1A presynaptic function in the mouse. Psychopharmacology 1994; 114:360-364
6.
Laaris N, Le Poul E, Laporte A, Hamon M, Lanfumey L: Differential effects of stress on presynaptic and postsynaptic 5-hydroxytryptamine-1A receptors in the rat brain: an in vitro electrophysiological study. Neuroscience 1999; 91:947-958
7.
McAllister-Williams RH, Young AH: The pathology of depression: a synthesis of the role of serotonin and corticosteroids, in Advances in Biological Psychiatry, vol 19. Edited by Ebert D, Ebmeier K. Basel, Switzerland, Karger, 1998, pp 170-198
8.
Steckler T, Holsboer F, Reul JM: Glucocorticoids and depression. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13:597-614

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1536-a - 1537

History

Published online: 1 September 2001
Published in print: September 2001

Authors

Affiliations

STUART WATSON, M.D., M.R.C.PSYCH.
ALLAN H. YOUNG, M.D., PH.D., M.R.C.PSYCH.
Newcastle Upon Tyne, U.K.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share